Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2012

View Archived Issues

Afatinib demonstrates significant improvements in PFS in the LUX-lung 3 phase III trial

Korean researchers patent novel antiviral compositions

Janssen Pharmaceutica presents new BACE1 inhibitors

Treventis prepares new anti-amyloid compounds

Novel cannabinoid CB1 receptor allosteric modulators discovered at University of Aberdeen

New efflux pump inhibitors for bacterial infections disclosed

Theravance presents new dual MABA bronchodilators for COPD

Ten major pharma companies form nonprofit organization

Almirall launches aclidinium in Europe

Cancer Therapeutics CRC synthesizes novel FADK inhibitors

Bayer submits European MAA for contraceptive patch

Identification of a new series of potent and selective NS5B inhibitors

Patrys cleared to commence phase I/IIa PAT-SM6 study

Murdoch Children's Research Institute receives grant to fight rotavirus

Intercell reports outcome of vaccine enhancement patch study in influenza

Plasma serotonin as indicator of stable heart disease outcomes

Scripps Research Institute receives grant for HIV research

The Leukemia & Lymphoma Society to support BET inhibitor program

Bayer College of Medicine presents novel Ndufs4-mutant mouse model

Sanofi and the TB Alliance to accelerate tuberculosis drug discovery

Cytochroma begins first of two identical phase III studies of CTAP-101

FDA approves sNDA for Aerospan inhalation aerosol

Dyax grants Kadmon exclusive license for anticancer candidate

Second phase I study confirms GAL-021's effects on respiration

Biovest provides update on planned MAA for NHL vaccine candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...